Jordi Remon, Thoracic Oncologist at CIOCC Barcelona, shared a post on X:
“Patients with NSCLC and asymptomatic brain mets, is a poor prognosis population.
The intensification of 1st line with addition antiCA4 drug (Nivo+Ipi+2 cycles CT like CheckMate9LA) did not reached primary endpoint in NIVIPI-Brain trial. CT+IO remains SoC and new agents are awaited.”
More posts featuring NSCLC.
